JAEGER and h/p/cosmos: An OEM partnership for over 30 years:

On the way back from MEDICA exhibition Düsseldorf last week I had the privilege to visit Andreas Kleinberg at JAEGER Medical headquarters in Höchberg / Würzburg.

Thanks a lot for the 3 decades of loyalty and excellent cooperation.

It was very inspiring to have updated conversations with Andreas Kleinberg and to see the new JAEGER showroom incorporating the latest Vyntus CPX with SentrySuite software for cardiopulmonary exercise testing CPET and 2 OEM JAEGER treadmills model LE 300CE with new TouchPro UserTerminal (MCU6) and a forerunner of the LE 200CE with the MCU5 UserTerminal.

h/p/cosmos is proud to call JAEGER a long term OEM partner since the year 1995 in distribution of medical grade treadmills.

JAEGER and h/p/cosmos likewise appreciate values like safety standards, durability, service support and regulatory investments made over decades leading to the h/p/cosmos equation: “Profit equals Margin minus Headache”.

We look forward to starting the next 30 years of co-operation with the JAEGER team.

And here some latest background information on regulatory compliance and on h/p/cosmos USPs:

Maximal Effort—CPET CriteriaThe lab tech smiles like the Saint of Oxygen,tightens the mask, whispers: “breathe for science”.One:The machine hums hymns of consumption.O₂ climbs the hill, then stalls—a plateau of polite refusal.The graph flattens,as if the soul itself has reachedits aerobic ceiling.Two:The heart is asked to keep pace.It shakes its head,folds its arms,sulks in the chest—a small…

Rationale There is substantial overlap of exertional symptoms in Long COVID (LC) and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), including intractable fatigue, post-exertional malaise (PEM), and orthostatic intolerance, but very little objective data linking the two. This study compares exercise pathophysiology in the two disorders and normal controls using invasive cardiopulmonary exercise testing (iCPET).

Methods Between January 2019 and December 2024, 1,518 patients underwent a clinical iCPET at Brigham and Women's Hospital. Exclusion criteria included morbid obesity (BMI > 40 kg/m²), severe anemia ([Hb] < 9.0 g/dL), elite athletes (peak VO₂ [pVO₂] > 120% predicted), sub-maximum effort (RER < 1.05), a primary pulmonary mechanical limit (VE @ AT/MVV > 0.7), and comorbidities such as active/treated cancer, interstitial lung disease, or other respiratory-related diseases.

iCPET results from 438 ME/CFS patients, 73 LC patients, and 43 symptomatic but otherwise normal controls were analyzed. pVO₂, peak cardiac output (pQc), peak right atrial pressure (pRAP), peak systemic oxygen extraction (pSOE; Ca-vO₂/[Hb]), and ventilatory inefficiency (VE/VCO₂ slope) were compared among groups. Statistical significance was determined using Kruskal-Wallis tests for global comparisons, with post-hoc Dunn tests for pairwise group comparisons. Holm-Bonferroni adjustments were applied to control for multiple comparisons.